{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T11:38:56Z","timestamp":1780573136245,"version":"3.54.1"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,9,10]],"date-time":"2018-09-10T00:00:00Z","timestamp":1536537600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Gastroenterol"],"published-print":{"date-parts":[[2019,1]]},"DOI":"10.1007\/s00535-018-1503-x","type":"journal-article","created":{"date-parts":[[2018,9,10]],"date-time":"2018-09-10T11:21:48Z","timestamp":1536578508000},"page":"87-95","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":102,"title":["Efficacy and safety of sofosbuvir\u2013velpatasvir with or without ribavirin in HCV-infected Japanese patients with decompensated cirrhosis: an open-label phase 3 trial"],"prefix":"10.1007","volume":"54","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5036-3457","authenticated-orcid":false,"given":"Tetsuo","family":"Takehara","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoya","family":"Sakamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuhei","family":"Nishiguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fusao","family":"Ikeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomohide","family":"Tatsumi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiyuki","family":"Ueno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Yatsuhashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuhiro","family":"Takikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsuo","family":"Kanda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minoru","family":"Sakamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akihiro","family":"Tamori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eiji","family":"Mita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuaki","family":"Chayama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gulan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shampa","family":"De-Oertel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hadas","family":"Dvory-Sobol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takuma","family":"Matsuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luisa M.","family":"Stamm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana M.","family":"Brainard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuhito","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masayuki","family":"Kurosaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,9,10]]},"reference":[{"key":"1503_CR1","unstructured":"American Association for the Study of Liver Diseases and the Infectious Diseases Society of America. HCV guidance: recommendations for testing, managing, and treating hepatitis C. \n                    http:\/\/www.hcvguidelines.org\/\n                    \n                  . Accessed 13 June 2018."},{"key":"1503_CR2","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1053\/j.gastro.2015.05.010","volume":"149","author":"M Charlton","year":"2015","unstructured":"Charlton M, Everson GT, Flamm SL, et al. Ledipasvir and sofosbuvir plus ribavirin for treatment of HCV infection in patients with advanced liver disease. Gastroenterology. 2015;149:649\u201359.","journal-title":"Gastroenterology"},{"key":"1503_CR3","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1016\/S1473-3099(16)00052-9","volume":"16","author":"M Manns","year":"2016","unstructured":"Manns M, Samuel D, Gane EJ, et al. Ledipasvir and sofosbuvir plus ribavirin in patients with genotype 1 or 4 hepatitis C virus infection and advanced liver disease: a multicentre, open-label, randomised, phase 2 trial. Lancet Infect Dis. 2016;16:685\u201397.","journal-title":"Lancet Infect Dis"},{"key":"1503_CR4","doi-asserted-by":"publisher","first-page":"2618","DOI":"10.1056\/NEJMoa1512614","volume":"373","author":"MP Curry","year":"2015","unstructured":"Curry MP, O\u2019Leary JG, Bzowej N, et al. Sofosbuvir and velpatasvir for HCV in patients with decompensated cirrhosis. N Engl J Med. 2015;373:2618\u201328.","journal-title":"N Engl J Med"},{"key":"1503_CR5","unstructured":"The Japan Society of Hepatology (JSH), Guidelines for the management of hepatitis C virus infection: edition 6.1, full version [Japanese]. 2018. \n                    http:\/\/www.jsh.or.jp\/files\/uploads\/R1__6.pdf\n                    \n                  . Accessed 13 June 2018."},{"key":"1503_CR6","unstructured":"Tanaka J, Estes C, Razavi H. An estimate of hepatitis C virus (HCV) Disease Burden in Japan. Presented at the 51st Annual Meeting of The Japanese Society of Hepatology (JSH) on 21 May 2015. 2015. Kumamoto, Japan. [Presentation Session 1 Hepatitis C]"},{"key":"1503_CR7","unstructured":"Ito S, Goto T, Yahashi H, et al. Investigation of actual condition of medical costs in liver cirrhosis and liver cancer patients due to hepatitis B or C infection for the Ministry of Health Labour and Welfare [Japanese]. 2016 [H28--002]. \n                    https:\/\/mhlw-grants.niph.go.jp\/niph\/search\/Download.do?nendo=2016&jigyoId=162131&bunkenNo=201619007A_upload&pdf=201619007A.zip\n                    \n                  . Accessed 13 June 2018."},{"key":"1503_CR8","first-page":"134","volume":"52","author":"The Japanese Liver Transplantation Society","year":"2017","unstructured":"The Japanese Liver Transplantation Society. Liver transplantation in Japan [Japanese]. Jpn J Transplant. 2017;52:134\u201347.","journal-title":"Jpn J Transplant"},{"key":"1503_CR9","doi-asserted-by":"publisher","first-page":"269","DOI":"10.3109\/00365528909093045","volume":"24","author":"I Albers","year":"1989","unstructured":"Albers I, Hartmann H, Bircher J, et al. Superiority of the Child\u2013Pugh classification to quantitative liver function tests for assessing prognosis of liver cirrhosis. Scand J Gastroenterol. 1989;24:269\u201376.","journal-title":"Scand J Gastroenterol"},{"key":"1503_CR10","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1002\/hep.1840070408","volume":"7","author":"C Infante-Rivard","year":"1987","unstructured":"Infante-Rivard C, Esnaola S, Villeneuve JP. Clinical and statistical validity of conventional prognostic factors in predicting short-term survival among cirrhotics. Hepatology. 1987;7:660\u20134.","journal-title":"Hepatology"},{"key":"1503_CR11","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1111\/hepr.12855","volume":"47","author":"T Genda","year":"2017","unstructured":"Genda T, Ichida T, Sakisaka S, et al. Survival in patients with Child\u2013Pugh class C cirrhosis: analysis of the liver transplant registry in Japan. Hepatol Res. 2017;47:1155\u201364.","journal-title":"Hepatol Res"},{"key":"1503_CR12","unstructured":"EPCLUSA (sofosbuvir and velpatasvir) tablets, for oral use US Prescribing Information. Gilead sciences, Inc. Foster City, CA. 2017. \n                    https:\/\/www.gilead.com\/~\/media\/Files\/pdfs\/medicines\/liver-disease\/epclusa\/epclusa_pi.pdf\n                    \n                  . Accessed 13 June 2018."},{"key":"1503_CR13","unstructured":"Epclusa 400\/100\u00a0mg film-coated tablets Summary of Product Characteristics (SmPC). Gilead sciences Ireland UC. County Cork, Ireland. 2017. \n                    https:\/\/www.ema.europa.eu\/docs\/en_GB\/document...Product...\/WC500211151.pdf\n                    \n                  . Accessed 13 June 2018."},{"key":"1503_CR14","unstructured":"Kim WR, Mannalithara A, Lee H, et al. Survival benefit of direct-acting antiviral therapy in patients with decompensated cirrhosis. Presented at The Liver Meeting 2017\u2014the 68th annual meeting of the American Association for the Study of Liver Diseases (AASLD); Washington, D. C. 2017 [Poster LB-27]."},{"key":"1503_CR15","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1002\/lt.24973","volume":"24","author":"A Kwong","year":"2018","unstructured":"Kwong A, Kim WR, Mannalithara A, et al. Decreasing mortality and disease severity in hepatitis C patients awaiting liver transplantation in the United States. Liver Transpl. 2018;24:735\u201343.","journal-title":"Liver Transpl"},{"key":"1503_CR16","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1159\/000470910","volume":"93","author":"F Ogata","year":"2017","unstructured":"Ogata F, Kobayashi M, Akuta N, et al. Outcome of all-oral direct-acting antiviral regimens on the rate of development of hepatocellular carcinoma in patients with hepatitis c virus genotype 1-related chronic liver disease. Oncology. 2017;93:92\u20138.","journal-title":"Oncology"},{"key":"1503_CR17","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.jhep.2017.08.030","volume":"68","author":"GN Ioannou","year":"2018","unstructured":"Ioannou GN, Green PK, Berry K. HCV eradication induced by direct-acting antiviral agents reduces the risk of hepatocellular carcinoma. J Hepatol. 2018;68:25\u201332.","journal-title":"J Hepatol"},{"key":"1503_CR18","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1016\/j.jhep.2016.06.019","volume":"65","author":"MC Cheung","year":"2016","unstructured":"Cheung MC, Walker AJ, Hudson BE, et al. Outcomes after successful direct-acting antiviral therapy for patients with chronic hepatitis C and decompensated cirrhosis. J Hepatol. 2016;65:741\u20137.","journal-title":"J Hepatol"}],"container-title":["Journal of Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00535-018-1503-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00535-018-1503-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00535-018-1503-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,22]],"date-time":"2019-09-22T14:38:22Z","timestamp":1569163102000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00535-018-1503-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9,10]]},"references-count":18,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,1]]}},"alternative-id":["1503"],"URL":"https:\/\/doi.org\/10.1007\/s00535-018-1503-x","relation":{},"ISSN":["0944-1174","1435-5922"],"issn-type":[{"value":"0944-1174","type":"print"},{"value":"1435-5922","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,9,10]]},"assertion":[{"value":"29 June 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 August 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 September 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Tetsuo Takehara has received honoraria and commercial research funding from Gilead. Naoya Sakamoto has received honoraria from Bristol-Myers Squibb, Merck Sharp & Dohme, and Gilead, and has received commercial research funding from Gilead, AbbVie, Bristol-Myers Squibb, Merck Sharp & Dohme, Otsuka, and Shionogi. Shuhei Nishiguchi has received honoraria from Gilead, and has received commercial research funding from Gilead, Toray and Merck Sharp & Dohme. Yoshiyuki Ueno received commercial research funding from Gilead, Bristol-Myers Squibb, AbbVie, and Merck Sharp & Dohme. Hiroshi Yatshuhashi has received commercial research funding from Chugai. Tatsuo Kanda has received commercial research funding from AbbVie, Merck Sharp & Dohme, Chugai, and Sysmex. Minoru Sakamoto has received honoraria from Bristol-Myers Squibb, Merck Sharp & Dohme, and Gilead, and has received commercial research funding from Gilead, AbbVie, Bristol-Myers Squibb, Merck Sharp & Dohme, Otsuka, and Shionogi. Akihiro Tamori has received honoraria from Gilead. Kazuaki Chayama has received honoraria from AbbVie, Merck Sharp & Dohme, Bristol-Myers Squibb, and Gilead. Gulan Zhang, Shampa De-Oertel, Hadas Dvory-Sobol, Takuma Matsuda, Luisa M. Stamm, and Diana M. Brainard are employees of and hold stock in Gilead Sciences. Yasuhito Tanaka has received honoraria from Bristol-Myers Squibb and Gilead Sciences, and has received commercial research funding from Chugai, AbbVie, Bristol-Myers Squibb, Janssen, and Gilead. Masayuki Kurosaki has served in an advisory role to AbbVie, Gilead, GlaxoSmithKline, and Otsuka, and has received honoraria from AbbVie, Bristol-Myers Squibb, Chugai, Daiichi Sankyo, Gilead, GlaxoSmithKline, Janssen, Merck Sharp & Dohme, Otsuka, and Toray. Fusao Ikeda, Tomohide Tatsumi, Yasuhiro Takikawa, and Eiji Mita, declare no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}